ClinicalTrials.gg
CompletedNCT03425149Updated Jul 5, 2019

Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults

A Phase 1 interventional study of VLA1601 and Placebo in Zika Virus and Zika Virus Infection, sponsored by Valneva Austria GmbH. Completed at 1 site in United States. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-05.

Sponsored by Valneva Austria GmbH (part of Valneva) · Phase 1, Interventional, and Prevention

From the registry’s dates

  • Primary completion was Jun 2018, 8 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
67
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Zika Virus Infection with a site in United States — 3 open to participants now, 3 under way, none of them phase 3. Zika Virus Infection · United States.

Enrollment
11th of 16
67 · median 91
Started
2018
with 3 others
Phase 1
12 of 23
none open now
Registered
13th of 23
by date
Lead sponsor
2 of 23
Valneva Austria GmbH

Among the 23 studies in Zika Virus Infection with a site in United States, this one is the 11th largest by enrollment of the 16 interventional ones that give a count, is one of 4 that started in 2018, is one of 12 in phase 1, and was the 13th registered.

Zika Virus Infection

78 studies on the registry are indexed under Zika Virus Infection; 8 are open to participants now.

Browse Zika Virus Infection studies →

Open to participants now

3 of the 23 studies in Zika Virus Infection with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 4 Zika Virus Infection studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 49 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Zika Virus Infection with a site in United States, or all of them as a file.
02

Study summary

In this Phase 1 study, two target dose levels of VLA1601, a purified, inactivated, whole Zika virus (ZIKV) vaccine candidate adsorbed on aluminum hydroxide (alum) will be evaluated: 6 antigen units (AU) and 3 AU of inactivated ZIKV vaccine. Each dose will be administered intramuscularly (i.m.) in the deltoid muscle on Days 0 and 28. In addition, an accelerated 2-dose vaccination schedule on Days 0 and 7 will be assessed for both doses.

03

Conditions studied

  • Zika Virus
  • Zika Virus Infection

Browse trials for

Keywords

  • vaccine
  • prevention
04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is 18 to 49 years of age on the day of screening (Visit 0);
  2. Subject has a (BMI) of ≥18.5 and \<30 kg/m2 on the day of screening (Visit 0);
  3. Subject has an understanding of the study and its procedures, agrees to its provisions, and gives written prior to any study-related procedures;
  4. Subject is generally healthy as determined by the Investigator's clinical judgment based on medical history, physical examination and screening laboratory tests;
  5. If subject is of :

    i. Subject has a negative serum pregnancy test at screening (Visit 0);

ii. Subject agrees to employ adequate measures for the duration of the study. This includes one of the following measures:

  1. Hormonal contraceptives (e.g. implants, birth control pills, patches) since ≥30 days prior to first vaccination;
  2. Intrauterine device;
  3. Barrier type of birth control measure (e.g. condoms, diaphragms, cervical caps);
  4. Vasectomy in the male sex partner ≥3 months prior to first vaccination;

Exclusion criteria

Exclusion Criteria:

  1. Subject has a history of known flavivirus infection, or vaccination with a licensed or flavivirus vaccine;
  2. Subject has plans to receive a licensed flavivirus vaccine during the course of the study;
  3. Subject has plans to travel to areas (including within the US) with active ZIKV, Japanese Encephalitis Virus (JEV), Dengue Virus (DENV) or Yellow Fever Virus (YFV) transmission during the course of the study or has travelled to a flavivirus-endemic area within 4 weeks prior to study enrollment;
  4. Subject is seropositive to ZIKV, JEV, DENV or West Nile virus (WNV);
  5. Subject has received an inactivated vaccine within 2 weeks or within 4 weeks prior to vaccination in this study;
  6. Subject has abnormal laboratory values, as determined by the Investigator, at screening (Visit 0);
  7. Subject tests positive for (HIV), surface antigen (HBsAg) or virus (HCV);
  8. Subject currently has or has a history of significant cardiovascular, respiratory (including asthma), metabolic, neurological (including Guillain-Barré syndrome), hepatic, rheumatic, , hematological, gastrointestinal or renal disorder;
  9. Subject has a disease or is undergoing a form of treatment or was undergoing a form of treatment within 4 weeks prior to study enrollment (i.e. subject randomized) that can be expected to influence immune response. Such treatment includes, but is not limited to, systemic or high dose inhaled (>800 μg/day of beclomethasone dipropionate or equivalent) , radiation treatment or other or cytotoxic drugs (use of inhaled (low dose), intranasal or topical steroids is permitted);
  10. Subject has a history of severe reactions or anaphylaxis;
  11. Subject has a history of any vaccine related contraindicating event (e.g., anaphylaxis, allergy to components of the candidate vaccine, other known );
  12. Subject had acute febrile infections within two weeks prior to vaccination in this study;
  13. Subject has donated blood within 30 days or received blood-derived products (e.g. plasma) within 90 days prior to vaccination in this study or plans to donate blood or use blood products during the course of the study;
  14. Subject has a rash, dermatological condition or tattoos that would, in the opinion of the Investigator, interfere with injection site reaction rating;
  15. Subject is currently enrolled or has participated in another clinical study involving an investigational medicinal product (IMP) or device within 30 days prior to study enrollment or is scheduled to participate in another clinical study involving an IMP or investigational device during the course of this study;
  16. Subject has plans to become pregnant during the course of the study, or is pregnant (positive serum pregnancy test at screening) or lactating at the time of study enrollment;
  17. Subject has a known or suspected problem with alcohol or drug abuse as determined by the Investigator;
  18. Subject is committed to an institution (by virtue of an order issued either by the judicial or the administrative authorities);
  19. Subject is a member of the team conducting this study or is in a dependent relationship with one of the study team members. Dependent relationships include close relatives (i.e., children, partner/spouse, siblings, parents) as well as employees of the Investigator or site personnel conducting the study;
  20. Subject has any condition that, in the opinion of the Investigator, may compromise the subject's well-being, might interfere with evaluation of study endpoints, or would limit the subject's ability to complete the study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    Treatment Group I

    0.5 ml (6 antigen units (AU)) of VLA1601 on Day 0 and 28, 0.5 ml Placebo on Day 7

    Biological: VLA1601 · Biological: Placebo

  • Experimental
    Treatment Group II

    0.5 ml (6 antigen units (AU)) of VLA1601 on Day 0 and 7, 0.5 ml Placebo on Day 28

    Biological: VLA1601 · Biological: Placebo

  • Experimental
    Treatment Group III

    0.25 ml (3 antigen units (AU)) of VLA1601 on Day 0 and 28, 0.25 ml Placebo on Day 7

    Biological: VLA1601 · Biological: Placebo

  • Experimental
    Treatment Group IV

    0.25 ml (3 antigen units (AU)) of VLA1601 on Day 0 and 7, 0.25 ml Placebo on Day 28

    Biological: VLA1601 · Biological: Placebo

  • Placebo comparator
    Treatment Group V

    0.5 ml Placebo on Day 0, 7 and 28

    Biological: Placebo

Interventions

  • BiologicalVLA1601

    purified inactivated ZIKV vaccine candidate adsorbed on alum

  • BiologicalPlacebo

    Phosphate buffered saline (PBS)

06

What researchers measure

Primary outcomes

  1. Rate of subjects with solicited adverse events including injection site and systemic reactions

    Time frame: within 7 days after any vaccination

Secondary outcomes

  1. Rate of subjects with solicited adverse events including injection site and systemic reactions

    Time frame: within 7 days after each vaccination

  2. Rate of subjects with any adverse events (AEs)

    Time frame: up to Day 56

  3. Rate of subjects with any adverse events (AEs)

    Time frame: during the entire study period, i.e., up to Day 208

  4. Rate of subjects with serious adverse events (SAEs)

    Time frame: up to Day 56

  5. Rate of subjects with serious adverse events (SAEs)

    Time frame: up to Day 208

  6. Rate of subjects with any IMP-related AEs

    IMP: Investigational Medicinal Product;

    Time frame: up to Day 56

  7. Rate of subjects with any IMP-related AEs

    IMP: Investigational Medicinal Product;

    Time frame: up to Day 208

  8. Rate of subjects with any IMP-related SAEs

    IMP: Investigational Medicinal Product;

    Time frame: up to Day 56

  9. Rate of subjects with any IMP-related SAEs

    IMP: Investigational Medicinal Product;

    Time frame: up to Day 208

  10. Geometric mean titer (GMT) for ZIKV-specific neutralizing antibody titer after last active vaccination

    GMT determined by plaque reduction neutralization test (PRNT)

    Time frame: 7 days after last active vaccination

  11. Geometric mean titer (GMT) for ZIKV-specific neutralizing antibody titer after last active vaccination

    GMT determined by plaque reduction neutralization test (PRNT)

    Time frame: 28 days after last active vaccination

  12. GMT for ZIKV-specific neutralizing antibody titer after first vaccination

    GMT determined by PRNT

    Time frame: 7 days after first vaccination

  13. GMT for ZIKV-specific neutralizing antibody titer after first vaccination

    for the Day 0, 28 schedule; GMT determined by PRNT

    Time frame: 28 days after first vaccination

  14. GMT for ZIKV-specific neutralizing antibody titer after first vaccination

    GMT determined by PRNT

    Time frame: Day 208 after first vaccination

  15. Rate of subjects with seroconversion after last active vaccination

    Time frame: 7 days after last active vaccination

  16. Rate of subjects with seroconversion after last active vaccination

    Time frame: 28 days after last active vaccination

  17. Rate of subjects with seroconversion after first vaccination

    Time frame: 7 days after first vaccination

  18. Rate of subjects with seroconversion after first vaccination

    for the Day 0, 28 schedule

    Time frame: 28 days after first vaccination

  19. Rate of subjects with seroconversion after first vaccination

    Time frame: 208 days after first vaccination

  20. Fold increase of ZIKV-specific neutralizing antibody titers after last active vaccination as compared to baseline

    Time frame: 7 after last active vaccination

  21. Fold increase of ZIKV-specific neutralizing antibody titers after last active vaccination as compared to baseline

    Time frame: 28 after last active vaccination

  22. Fold increase of ZIKV-specific neutralizing antibody titers after first vaccination as compared to baseline

    Time frame: 7 days after first vaccination

  23. Fold increase of ZIKV-specific neutralizing antibody titers after first vaccination as compared to baseline

    for the Day 0, 28 schedule

    Time frame: 28 days after first vaccination

  24. Fold increase of ZIKV-specific neutralizing antibody titers after first vaccination as compared to baseline

    Time frame: 208 days after first vaccination

07

Study locations

1 site
  • New Orleans Center for Clinical Research
    Knoxville, Tennessee 37920, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Jun 2018, 4 months.

Of 21 phase 1 interventional studies under Zika Virus Infection, half reached primary completion within 15 months of starting (the median); a quarter within 8 and three quarters within 25. This study's 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2018
First posted
Feb 7, 2018
StartActual
Feb 24, 2018
Primary completionActual
Jun 26, 2018
CompletionActual
Nov 16, 2018
Last update
Jul 5, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03425149
Responsible party
Sponsor
First posted
Feb 7, 2018
Start date
Feb 24, 2018
Primary completion
Jun 26, 2018
Completion
Nov 16, 2018
Last update
Jul 5, 2019

Study contacts

Katrin Dubischar
study director · Valneva Austria GmbH

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion